BG Medicine (BGMD) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq ends lower as oil prices surge ahead of earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
BG Medicine Reports Third Quarter 2014 Financial Results
November 13, 2014 6:30 AM ESTNet Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013
Company Retains Investment Bank to Explore Strategic Alternatives
WALTHAM, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- BGMedicine, Inc. (Nasdaq: BGMD), the developer of the BGM Galectin-3®Test, today reported financial results for the third quarter... More



